Background: Sirolimus-eluting stent (SES) is generally known as the powerful suppression of neointimal hyperplasia. In selected cases, the safety and efficacy of SES were revealed until 4 years. We would like to have the evidence of promising results at long-term (2 year) follow-up in real world practice. Method: 692 patients (male 66.3%, age 61 짹 10) were consecutively enrolled who underwent coronary intervention with SES since April 2003 to July 2004. 2 years clinical outcomes and angiographic follow-up results were analyzed, and were compared with the pooled data of bare metal stent, which were implanted since January 2003 to December. Results: 2 years adverse cardiac events were 4.6 % in SES, 12.8 % in BMS (p<0.001). Other data are in the following table. 2 years clinical follow-up was available 87.3%. Angiographic follow up was available in 54.2%. Conclusion: This analysis of 2 year data collected by single center experience in real world practice suggests a high degree of safety and efficacy of SES, with a similar rate of stent thrombosis in BMS.